These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 18050603)

  • 1. [Chronic fatigue. IV--Assessment of a 40-year-old patient].
    Mettler J; Battegay E; Zimmerli L
    Praxis (Bern 1994); 2007 Nov; 96(45):1773-5. PubMed ID: 18050603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Thyrotoxicosis induced by interferonotherapy of chronic hepatitis C in a woman with Hashimoto's thyroiditis].
    Kozielewicz D; Junik R; Halota W
    Pol Merkur Lekarski; 2014 Aug; 37(218):108-10. PubMed ID: 25252446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapse to opioid use after treatment of chronic hepatitis C with pegylated interferon and ribavirin.
    Matthews AM; Fireman M; Zucker B; Sobel M; Hauser P
    Am J Psychiatry; 2006 Aug; 163(8):1342-7; quiz 1479. PubMed ID: 16877644
    [No Abstract]   [Full Text] [Related]  

  • 4. Hashimoto's encephalopathy after interferon therapy for hepatitis C virus in adult liver transplant recipient accompanied by post-transplant lymphoproliferative disorder related to Epstein-Barr virus infection.
    Hori T; Oike F; Hata K; Nishikiori M; Ogura Y; Ogawa K; Takada Y; Egawa H; Nguyen JH; Uemoto S
    Transpl Infect Dis; 2010 Aug; 12(4):347-52. PubMed ID: 20456713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple fixed drug eruption with interferon/ribavirin combination therapy for hepatitis C virus infection.
    Sidhu-Malik NK; Kaplan AL
    J Drugs Dermatol; 2003 Oct; 2(5):570-3. PubMed ID: 14558408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lingual hyperpigmentation in a patient with chronic infection].
    López Peláez MV; González Díaz P; Téllez Molina MJ; Vergas García J
    Enferm Infecc Microbiol Clin; 2013 Apr; 31(4):264-5. PubMed ID: 23260387
    [No Abstract]   [Full Text] [Related]  

  • 7. Depression in chronic hepatitis: the virus, the drug, or the ethnic background?
    Ferenci P; Staufer K
    Liver Int; 2008 Apr; 28(4):429-31. PubMed ID: 18339069
    [No Abstract]   [Full Text] [Related]  

  • 8. Fibrosing cholestatic hepatitis after successful interferon and ribavirin therapy for recurrent hepatitis C post living related liver transplantation: a case report.
    Yamamoto T; Tanaka S; Uenishi T; Kanazawa A; Kubo S; Hirohashi K
    Osaka City Med J; 2014 Dec; 60(2):95-100. PubMed ID: 25803885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatment for chronic hepatitis C.
    Davis GL
    Rev Gastroenterol Disord; 2001; 1(2):59-72. PubMed ID: 12120176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.
    Nachnani JS; Rao GA; Bulchandani D; Pandya PK; Alba LM
    Ann Hematol; 2010 Feb; 89(2):121-5. PubMed ID: 19565241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Side effects of interferon therapy for chronic hepatitis C].
    Arase Y
    Nihon Rinsho; 2006 Jul; 64(7):1363-7. PubMed ID: 16838657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
    Schaefer M; Schmidt F; Folwaczny C; Lorenz R; Martin G; Schindlbeck N; Heldwein W; Soyka M; Grunze H; Koenig A; Loeschke K
    Hepatology; 2003 Feb; 37(2):443-51. PubMed ID: 12540795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current therapies for chronic hepatitis C.
    Ferguson MC
    Pharmacotherapy; 2011 Jan; 31(1):92-111. PubMed ID: 21182362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antiviral therapy of hepatitis C].
    Erhardt A; Petry W; Ebel M; Jablonowski H; Heintges T; Häussinger D
    Z Gastroenterol; 2000 Mar; 38(3):259-69. PubMed ID: 10768250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consensus conference. Treatment of hepatitis C.
    Agence Nationale d'Accréditation et d'Evaluation en Santé (ANAES)
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B303-20. PubMed ID: 12180305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment.
    Watson B; Conigrave KM; Wallace C; Whitfield JB; Wurst F; Haber PS
    Drug Alcohol Rev; 2007 May; 26(3):231-9. PubMed ID: 17454012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of chronic hepatitis C].
    Rókusz L
    Orv Hetil; 2004 Aug; 145(32):1649-53. PubMed ID: 15384863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and management of chronic hepatitis C.
    Sharara AI
    J Med Liban; 1999; 47(6):339-42. PubMed ID: 10758707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chronic hepatitis C: what to do if the first treatment failed?].
    Asselah T
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B50-9. PubMed ID: 12180309
    [No Abstract]   [Full Text] [Related]  

  • 20. Telaprevir use in a chronic hepatitis C patient with hemophilia.
    Guner R; Tufan ZK
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):248. PubMed ID: 24366457
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.